Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN   3:59:58 PM EDT
572.69
+3.32 (+0.58%)
Products

FDA Accepts REGEN-COV For Priority Review For Treatment And Prophylaxis Of COVID-19

Published: 10/14/2021 11:35 GMT
Regeneron Pharmaceuticals, Inc. (REGN) - FDA Accepts Regen-cov® (casirivimab and Imdevimab) for Priority Review for Treatment and Prophylaxis of Covid-19.
Regeneron Pharmaceuticals Inc - FDA Has Assigned a Target Action Date of April 13, 2022.
Regeneron - Second Bla Submission Focusing on Treatment of Patients Hospitalized Due to Covid-19 is Expected to Be Submitted Later This Year.
Regeneron Pharmaceuticals - FDA Planning to Hold an Advisory Committee Meeting to Discuss Regen-cov Application in Advance of April 13, 2022.